PON1 and type 1 diabetes mellitus: NO bioavailability was found to be reduced in all groups compared with controls (P < 0.05 for all), whereas SO production was increased only in those with a high inflammatory score (P < 0.05; Figure 1), and PON-1 activity was reduced in patients with Type 1 diabetes and low levels of both HDL and inflammation.